TW202146426A - 使用肽及醫藥組合物治療發炎疾病 - Google Patents

使用肽及醫藥組合物治療發炎疾病 Download PDF

Info

Publication number
TW202146426A
TW202146426A TW110108016A TW110108016A TW202146426A TW 202146426 A TW202146426 A TW 202146426A TW 110108016 A TW110108016 A TW 110108016A TW 110108016 A TW110108016 A TW 110108016A TW 202146426 A TW202146426 A TW 202146426A
Authority
TW
Taiwan
Prior art keywords
gly
compound
substituted
leu
formula
Prior art date
Application number
TW110108016A
Other languages
English (en)
Chinese (zh)
Inventor
柳源相
鐘弘 朴
Original Assignee
南韓商柳柳製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商柳柳製藥股份有限公司 filed Critical 南韓商柳柳製藥股份有限公司
Publication of TW202146426A publication Critical patent/TW202146426A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW110108016A 2020-03-05 2021-03-05 使用肽及醫藥組合物治療發炎疾病 TW202146426A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985603P 2020-03-05 2020-03-05
US62/985,603 2020-03-05

Publications (1)

Publication Number Publication Date
TW202146426A true TW202146426A (zh) 2021-12-16

Family

ID=77890982

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110108016A TW202146426A (zh) 2020-03-05 2021-03-05 使用肽及醫藥組合物治療發炎疾病

Country Status (7)

Country Link
US (1) US20230146455A1 (enExample)
EP (1) EP4114430A4 (enExample)
JP (1) JP2023516677A (enExample)
KR (1) KR20220149745A (enExample)
CA (1) CA3170606A1 (enExample)
TW (1) TW202146426A (enExample)
WO (1) WO2021191689A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037415B2 (en) 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
US12575976B2 (en) 2021-11-08 2026-03-17 Recker Medical Urine quantifying bed pad
MX2024006997A (es) * 2021-12-13 2024-06-19 Eyebiokorea Inc Composicion para el tratamiento de la degeneracion macular que comprende un nuevo peptido.
WO2025149851A2 (en) * 2024-01-12 2025-07-17 Yuyu Pharma, Inc. Methods for treating inflammatory diseases
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
ES2822289T3 (es) * 2016-04-08 2021-04-30 Eyebio Korea Péptido a base de colágeno tipo II alfa-1 para su uso en el tratamiento de la degeneración macular
KR101795653B1 (ko) * 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물
US12037415B2 (en) * 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物

Also Published As

Publication number Publication date
EP4114430A2 (en) 2023-01-11
WO2021191689A3 (en) 2021-12-23
EP4114430A4 (en) 2025-05-14
KR20220149745A (ko) 2022-11-08
CA3170606A1 (en) 2021-09-30
WO2021191689A2 (en) 2021-09-30
US20230146455A1 (en) 2023-05-11
JP2023516677A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
KR20220149745A (ko) 펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물
RU2439074C2 (ru) ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
US11365189B2 (en) Heterocyclic inhibitors of tyrosine kinase
TWI865470B (zh) 治療眼睛疾病之肽及醫藥組合物
CN107635404A (zh) 用于治疗疾病的mct4抑制剂
WO2018225961A1 (ko) 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
CN117164583A (zh) 一种靶向irak4蛋白降解的化合物及其应用
EP4357339A1 (en) Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method therefor, and use thereof
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
TW201718548A (zh) 哌嗪（ｐｉｐｅｒａｚｉｎｅ）衍生物
EP4229058B1 (en) Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
EP3253386B1 (en) Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
WO2021114691A1 (zh) 含氮并环化合物、其制备方法及用途
CN113072521B (zh) RORγt抑制剂及其在药物中的应用
CA3119921C (en) Peptides and pharmaceutical compositions for treating eye diseases
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
WO2022152140A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
HK40093954A (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
HK40093954B (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
HK40061089A (en) Peptides and pharmaceutical compositions for treating eye diseases
HK40061089B (en) Peptides and pharmaceutical compositions for treating eye diseases